Introduction {#j_hukin-2019-0114_s_001}
============

Ketosis is defined as elevated circulating levels of ketone bodies (beta-hydroxybutyrate; βHB, acetoacetate, acetone)\]. Traditionally, ketosis was achieved through fasting ([@j_hukin-2019-0114_ref_003]), a very low-carbohydrate ketogenic diet (VLCKD; [@j_hukin-2019-0114_ref_026], [@j_hukin-2019-0114_ref_024], [@j_hukin-2019-0114_ref_025]), or under pathological conditions where insulin levels were insufficient to prevent rapid ketogenesis (i.e. mismanaged Type-1 Diabetes). The VLCKD usually does not require caloric restriction and was originally used as an effective dietary replacement to fasting due to its overlapping mechanisms ([@j_hukin-2019-0114_ref_020]) for epileptic seizures ([@j_hukin-2019-0114_ref_023]). Currently, the VLCKD is being explored as a metabolic tool for other neurological disorders, obesity, inflammatory disorders, Type-1 and -2 diabetes mellitus, polycystic ovarian syndrome, and cancer, amongst others ([@j_hukin-2019-0114_ref_015]; [@j_hukin-2019-0114_ref_023]; [@j_hukin-2019-0114_ref_027]; [@j_hukin-2019-0114_ref_034]). The VLCKD has also been investigated for longevity ([@j_hukin-2019-0114_ref_019]; [@j_hukin-2019-0114_ref_029]), along with cognitive and physical performance ([@j_hukin-2019-0114_ref_019]; [@j_hukin-2019-0114_ref_038]; [@j_hukin-2019-0114_ref_040]).

Emerging interest into the metabolic influence of the VLCKD on athletic performance began in the early 1980s where untrained and trained athletes were able to maintain or improve performance even in the absence of sufficient dietary carbohydrates ([@j_hukin-2019-0114_ref_026], [@j_hukin-2019-0114_ref_024]). Since that time, numerous studies have explored the metabolic influence of diet on aerobic ([@j_hukin-2019-0114_ref_041]) and anaerobic ([@j_hukin-2019-0114_ref_018]; [@j_hukin-2019-0114_ref_022]; [@j_hukin-2019-0114_ref_040]) performance to determine if major shifts in substrate metabolism translate to altered performance outcomes. However, lifestyle modifications can be difficult for some to maintain ([@j_hukin-2019-0114_ref_005]). Simultaneously, interest has arisen to develop forms of ketone bodies that can be exogenously administered. Several exogenous ketone formulations have been developed including R-βHB + S-βHB-salt (βHB-salt), βHB-salt + Medium Chain Triglycerides (βHB-salt+MCT), and ketone esters, each of which elevated circulating levels of ketone bodies when orally administered ([@j_hukin-2019-0114_ref_014]). Comparative analysis in human subjects also demonstrated the ability of exogenous ketones to increase circulating ketone levels ([@j_hukin-2019-0114_ref_036]). With the emergence of commercially available exogenous ketone formulations, research has focused on exploring their use in athletic performance ([@j_hukin-2019-0114_ref_004]; [@j_hukin-2019-0114_ref_008]; [@j_hukin-2019-0114_ref_009]).

Exogenous ketone supplements that have been used to manipulate metabolism in studies investigating athletic performance can be divided into two categories: Ketone Esters ([@j_hukin-2019-0114_ref_004]; [@j_hukin-2019-0114_ref_008]; [@j_hukin-2019-0114_ref_016]) and βHB-salts ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]), with the former inducing greater elevations in βHB with correlated changes in systemic metabolism ([@j_hukin-2019-0114_ref_036]). To date, one trial showed exercise improvements ([@j_hukin-2019-0114_ref_004]), three trials showed neutral effects ([@j_hukin-2019-0114_ref_008]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]), and two trials showed negative effects using exogenous ketone supplementation ([@j_hukin-2019-0114_ref_016]; [@j_hukin-2019-0114_ref_021]). The likely explanation for divergent findings is the heterogeneity of exercise duration, task, and intensity, along with divergent ketone formulations and dose. Additionally, most trials involve cycling protocols ([@j_hukin-2019-0114_ref_004]; [@j_hukin-2019-0114_ref_016]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_039]; [@j_hukin-2019-0114_ref_031]). Thus, further research into the ergogenic or ergolytic potential of various forms of ketone supplementation in other performance contexts is warranted.

Interestingly, all βHB-salt trials done thus far have utilized varying dosages (140-536 mg/kg), but resulted in similar elevations in R-βHB ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]), indicating that gut absorption may be a limiting factor in rapidly raising R-βHB with βHB-salts. However, [@j_hukin-2019-0114_ref_014] found that a βHB-salt+MCT combination prolonged R-βHB elevation in rats, and this was observed to be a superior formula. Additionally, it has been previously reported that MCTs are rapidly metabolized to R-βHB ([@j_hukin-2019-0114_ref_002]; [@j_hukin-2019-0114_ref_033]) and produce a more robust thermogenic effect than other dietary fat sources ([@j_hukin-2019-0114_ref_017]; [@j_hukin-2019-0114_ref_033]). However, the βHB-salt+MCT combination has never been explored for exercise performance and ketone supplementation has not been applied to a single intermediate distance running bout. Consequently, we sought to explore the ability of a commercially available exogenous ketone mixture of βHB-salt+MCT to impact physiologic, metabolic, perceptional, and performance responses to intermediate distance running performance in a randomized, cross-over design in recreational, college-age endurance athletes. We hypothesized that this βHB-salt+MCT drink would alter blood metabolites and metabolism, but neither perception nor athletic performance, in line with previous work exploring βHB-salt alone ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_036]; [@j_hukin-2019-0114_ref_039]).

Methods {#j_hukin-2019-0114_s_002}
=======

Experimental Approach to the Problem {#j_hukin-2019-0114_s_002_s_001}
------------------------------------

A double-blind placebo-controlled crossover design was employed consisting of one familiarization trial and two experimental trials. During the familiarization session, participants were informed of all procedures and familiarized with all performance measures to reduce the possibility of a learning effect. The familiarization trial was identical to experimental trials except that participants consumed no supplement prior to exercise. After familiarization, participants completed two experimental conditions (ketone or placebo), the order of which was completed in a randomized and counterbalanced fashion separated by 7 days. On experimental days, participants consumed either 300 mg.kg^-1^ body weight of the ketone supplement (βHB-salt+MCT) or a flavor matched placebo (PLA) 60 min prior to performing a 5-km running time trial on a treadmill. Plasma glucose and ketones were measured at baseline, 60 min post supplement ingestion, and immediately following the time trial. Plasma blood lactate concentration was measured before and after the time trial. Other variables evaluated were (a) 5-km running time, (b) RPE (RPE-Overall; RPE-Chest; RPE-Legs), (c) heart rate, (d) affect, (e) session RPE, (f) session affect, and (g) 500-m split times during the 5-km time trial. The RPE, heart rate, and affect were taken every 500-m during the 5-km time trial. In addition, during the time trial oxygen uptake (VO~2~), carbon dioxide production (VCO~2~), minute ventilation (V~E~) and respiratory exchange ratio (RER), were assessed and derived from indirect calorimetry. Testing sessions were conducted at the same time each day at a room temperature between 19-210C and a relative humidity of 35-40%. All testing took place at the Exercise Science Laboratory of Grove City College.

Participants {#j_hukin-2019-0114_s_002_s_002}
------------

Ten male, recreational runners (age: 20.8 ± 1.03 years; body height: 175.6 ± 4.9 cm; body mass: 68.9 ± 5.6 kg; body fat: 13.4 ± 3.6%; lean body mass: 59.6 ± 3.1 kg; body mass index: 22.4 ± 1.9 kg/m^2^; running distance per week: 34.6 ± 5.5 km) volunteered to participate in this study. Participants were recruited directly from local running clubs, and by advertising within the local community. Included men: (a) currently run an average of 32 km per week; (b) were between the ages of 18-35; and (c) had completed a 5-km distance run under 30 min within the last 3 months. Participants were not currently taking medications or following a low-carbohydrate or ketogenic diet, or currently consuming nutritional ketone supplements. Participants were prohibited from using any ergogenic aids for one month preceding the study and were asked to refrain from taking any performance enhancing supplement(s) other than the experimental beverage during the study. Runners were instructed not to change their regular exercise training and dietary habits for the duration of the study, and they were told not to exercise prior to testing. Participants were instructed to refrain from caffeine, and alcohol consumption for 48 hours, physical activity for 24 hours, and food and drink for 3 hours before each exercise test ([@j_hukin-2019-0114_ref_001]; [@j_hukin-2019-0114_ref_010]). Participants were instructed to maintain a training and dietary log for 3 days before the first experimental trial. They were provided with a copy of their pre-trial log, and were instructed to have the same dietary intake and physical activity during the 48 hours before the other trials. Dietary logs were checked to ensure compliance and we were satisfied that all of the participants adhered to the instructions given and that the food and drinks consumed before each trial were the same. Before enrolling in the investigation, participants were fully informed of any risks and discomforts associated with the experiments prior to giving their written informed consent to participate. The experimental protocol was approved by the Institutional Review Board of Grove City College prior to implementation.

Procedures {#j_hukin-2019-0114_s_002_s_003}
----------

*Familiarization Testing*. At the first laboratory visit, all the experimental procedures were explained to the participants. Participants underwent an orientation involving practice of treadmill running and familiarization of the various experimental instruments, equipment, affect and perceived exertion. Affect was measured using a validated 11-point Feeling Scale ([@j_hukin-2019-0114_ref_012]) with participants informed that their responses should reflect the affective or emotional components of the exercise and not the physical sensation of effort or strain. The OMNI Walk/Run Perceived Exertion Scale ([@j_hukin-2019-0114_ref_030]) was used to measure the physical perceptions of exertion for overall body (RPE-O), legs (RPE-L) and chest (RPE-C). Following the orientation session, anthropometric measures were obtained including body height (cm), body mass (kg), fat free mass (kg) and fat mass (% and kg). Body height (cm) was measured using a physician's scale (Detecto, Webb City, MO). Body mass (kg) and body composition (fat and lean mass) were estimated using a Tanita bioelectrical impedance analyzer (BIA) (TBF-310GS Tanita Corporation of America, Arlington Heights, Illinois).

*Experimental Trials*. On experimental testing days, participants were given either a commercially available βHB-salt+MCT or a flavor-matched PLA. The beverages were served cold (\~6 °C) and were provided to participants 60 min before the test began. Participants were instructed to drink the beverage within 2 min of receiving it. To ensure a double-blinded design, each drink was presented to participants in an opaque sports bottle. After consumption of the beverage, participants were instructed to sit quietly for 1 hour.

Before the start of the time trial, participants completed a 5-min warm-up run on the treadmill (TMX425C treadmill; Trackmaster, Newton, KS, USA). Immediately thereafter, the treadmill was brought to a standstill (0 km∙hr^-1^). At this point all timing devices were reset, the distance covered on the treadmill monitor was reset, and a 5-s count down was given to signal that the time trial has begun ([@j_hukin-2019-0114_ref_028]). Participants were instructed to finish the 5-km run as fast as possible on a motorized treadmill at 0.0% grade. Participants were provided with feedback on the distance (at regular 500-m intervals) covered during each 5-km time trial and were not informed of the overall performance time until completion of the final testing session. The heart rate (Polar Electro, Kempele, Finland), RPE (RPE-Overall; RPE-Chest; RPE-Legs) and affect (Feeling Scale) were recorded at 500-m intervals during the time trial. During the time trial, participants were allowed to adjust their pace via control buttons located on the treadmill. The speed indicator was concealed from the participant's view throughout the time trial. Therefore, participants regulated their treadmill pace according to their perceived exertion associated with the intensity of the exercise and their subjective feelings of their running capabilities. During each treadmill run all timing devices were removed from the participant's sight. Immediately upon cessation of treadmill exercise, participants estimated their perceived exertion and affect, and a final heart rate measurement was taken. Lastly, ratings of perceived exertion and affect for the entire exercise session (session RPE and session affect) were obtained 5 min following the time trial. Gas samples were collected throughout the time trial using a metabolic cart (TrueOne 2400® Metabolic Measurement System, Parvo Medics, Inc., Sandy, UT). To establish any learning effect after completion of the two experimental trials, 5-km time to completion was compared between the supplement and the placebo trial using a paired samples t-test. No significant difference between trials was observed (*p* = 0.577). In addition, intraclass correlation coefficients were computed for all conditions of all participants of the 5KTT and was reported to be ICC *r* = 0.870 with a 95% confidence interval of 0.584--0.965.

*Metabolic Gases*. Prior to each 5KTT, open-circuit spirometry was calibrated with room air and gases of known concentrations, which was used to estimate VO~2~ (ml^∙^kg^−1^∙min^−1^) by sampling and analyzing breath-by-breath expired gases. Expired gases --- VO~2~, VCO~2~, V~E~, and RER, were monitored continuously during exercise and expressed as 30-s averages.

*Blood Sampling*. Finger-tip blood samples were collected and immediately processed for plasma blood lactate (Lactate Plus, Nova Biomedical), ketones (*R*-βHB; Precision Xtra, Abbott Diabetes Care Inc., Almeda, CA) and glucose (Precision Xtra, Abbott Diabetes Care Inc., Almeda, CA) concentrations. Fingertip capillary samples were collected using a lancet following cleaning with alcohol swab and dried. The first droplet was wiped away with a cotton swab to remove any alcohol and the subsequent droplets were used for analysis. Blood samples were measured at baseline, 60 min post-supplement ingestion, and at the end of the time trial.

*Supplementation*. The supplement used in this study consisted of βHB-salt+Medium Chain Triglyceride (KETO//OS 2.1 Orange Dream, Pruvit, Melissa, TX, USA). Participants consumed 300 mg.kg^-1^ of body mass of the ketone supplement powder mixed with approximately 237 ml of cold (\~6 °C) water prior to ingestion. The supplement contained a calculated 9.0 βHB racemic salt (50% *R*-βHB and 50% *S*-βHB) and reported 7g MCT. A complete list of the ingredients and the relative dose of each ingredient is provided in [Table 1](#j_hukin-2019-0114_tab_001){ref-type="table"}. Volume for the drinks was measured with a graduated cylinder and the dry ingredients were measured to the nearest 0.001 g on a calibrated balance scale (Denver Instrument, Bohemia, NY). When receiving the PLA, participants consumed an equal amount of water with MiO Orange Tangerine Liquid Enhancer (0 mg caffeine, 0 kcal; Kraft Foods; MiO, Northfield, IL, USA). The ketone supplement, and PLA drink were similar in volume, texture, and appearance. The taste of the drinks was slightly different, and there remains the possibility that participants were able to identify the drinks. To avoid the placebo effect in the experimental trials, we did not inform participants about the names of the drinks and we presented both drinks as having similar ergogenic properties.

###### 

Ingredients contained in 1 dose of the ketone supplement in absolute serving size

  Ingredient                         Amount per serving
  ---------------------------------- --------------------
  Total Calories                     110 Kcal
  β-hydroxybutyrate (βHB)            9.0 g\*
  Medium-Chain Triglycerides (MCT)   7 g
  Sodium                             1.4 g
  Potassium                          47 mg
  Total Carbohydrates                3 g
  Sugars                             2 g
  Protein                            1 g

*Data are reported values based on product labeling. Note. \* = estimated grams of β-hydroxybutyrate (βHB) from 1) calculation of the molecular equivalence of the mineral load to (βHB) and 2) calculation of the difference between total product weight and non-βHB ingredient weights*.

Statistical Analysis {#j_hukin-2019-0114_s_002_s_004}
--------------------

Statistical analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL). Statistical significance was set *a priori* at *p* \< 0.05. Descriptive statistics were calculated for all variables. Data were tested for normality using the Shapiro-Wilk test. Performance data (5-km running time), mean exercise heart rate, RER, VO~2~, VCO~2~, V~E~, affect, RPE-Chest, RPE-Legs, RPE-Overall, session RPE and session affect were analyzed using a paired-samples *t*-Test. A 2 × 10 (condition x distance during the 5-km time trial) repeated measures analysis of variance was conducted to assess the effect of time, treatment, and interaction between time and treatment, on heart rate, affect, RPE-Chest, RPE-Legs, RPE-Overall, and time covered at each 500-m interval during the 5-km time trial. A 2 (condition, supplement vs placebo) x 3 (rest, 60 min post ingestion, and at end of exercise) repeated measures analysis of variance was conducted to assess the effect of time, treatment, and interaction between time and treatment, on plasma glucose and ketones. A 2 x 2 (before and after exercise) repeated measures analysis of variance was conducted to assess the effect of time, treatment, and interaction between time and treatment, on plasma lactate. The assumption of sphericity was confirmed using Mauchly\'s test. Greenhouse-Geisser epsilon corrections were used when the sphericity assumption was violated. Effect sizes (Cohen's d) were calculated and interpreted as: small effect \> 2; medium effect \> 0.5; large effect \> 0.8.

Results {#j_hukin-2019-0114_s_003}
=======

Time Trial Performance {#j_hukin-2019-0114_s_003_s_001}
----------------------

No significant difference (*p* = 0.100) was observed between the βHB-salt+MCT supplement (1430.0 ± 187.7 s) and the PLA (1488.3 ± 243.8 s) in time to complete the 5KTT ([Figure 1](#j_hukin-2019-0114_fig_001){ref-type="fig"}; [Table 2](#j_hukin-2019-0114_tab_002){ref-type="table"}). However, in comparison to the mean time for the PLA trial, βHB-salt+MCT supplement ingestion resulted in an average non-significant decrease in time to completion of 58.3 s (4.06%; 95% CI: - 130.12 -- 13.52; ES = 0.27). The individual range in reduced time to completion across participants was 43 - 214 s. Eight participants (80%) ran faster after consuming the βHB-salt+MCT supplement, while two participants (20%) ran faster after consuming the PLA.

![Mean and individual 5-km performance time following exogenous ketone supplement and placebo ingestion.](hukin-72-115-g001){#j_hukin-2019-0114_fig_001}

###### 

Physiological, metabolic and perceptual data for 5-km time-trial performance between the supplement and the placebo (N = 10)

  Variable                Ketone Supplement   Placebo          *p*‐value   Effect Size
  ----------------------- ------------------- ---------------- ----------- -------------
  TT performance (s)      1430.0 ± 187.7      1488.3 ± 243.8   0.100       0.27
  HR (b.min^-1^)          173.1 ± 15.7        178.8 ± 7.9      0.322       0.46
  RPE- O                  5.5 ± 1.3           5.3 ± 1.4        0.593       0.15
  RPE- C                  5.0 ± 1.4           5.0 ± 1.3        1.000       0.00
  RPE- L                  5.3 ± 1.5           5.0 ± 1.6        0.434       0.19
  Affect                  2.3 ± 1.8           1.8 ± 1.8        0.143       0.28
  VO~2~ (L.min-^1^)       3.0 ± 0.5           3.0 ± 0.5        0.665       0.08
  VO~2~ (ml.kg.min^-1^)   44.2 ± 5.6          43.8 ± 5.9       0.695       0.07
  VCO~2~ (L.min^-1^)      3.0 ± 0.6           2.9 ± 0.6        0.521       0.12
  V~E~ (L.min^-^1)        70.9 ± 14.8         69.4 ± 15.0      0.607       0.10
  RER                     0.99 ± 0.04         0.98 ± 0.04      0.655       0.24
  Session RPE             6.2 ± 1.3           7.3 ± 1.6        0.093       0.76
  Session Affect          2.6 ± 1.6           2.0 ± 2.3        0.456       0.3

Data are Mean ± SD. Note. TT = time trial; HR = heart rate; RPE-O = RPE for overall body; RPE-C = RPE for chest; RPE-L = RPE for legs; RPE = rating of perceived exertion (OMNI rating of exertion); RER = Respiratory exchange ratio. Effect sizes, \< 0.2 = trivial; 0.2 to 0.49 = small; 0.5 to 0.79 = moderate; \> 0.8 = large

Physiological, Metabolic and Perceptual Responses {#j_hukin-2019-0114_s_003_s_002}
-------------------------------------------------

Blood *R*-βHB increased from baseline under the βHB-salt+MCT condition, and levels were elevated throughout the entire protocol compared to the PLA (*p* \< 0.05 for all; [Figure 2A)](#j_hukin-2019-0114_fig_002){ref-type="fig"}. Blood lactate and glucose concentration rose from baseline to the end of exercise (*p* \< 0.001), but there were no significant differences seen between conditions at any time point (*p* \> 0.05; [Figure 2B](#j_hukin-2019-0114_fig_002){ref-type="fig"} and [C)](#j_hukin-2019-0114_fig_002){ref-type="fig"}. Heart rate and RPE (chest, legs, and overall) increased significantly during exercise (*p* \< 0.001), while affect deceased significantly during exercise (*p* \< 0.001), however, there were no significant effects for treatment for any of the aforementioned variables (*p* \> 0.05). In addition, no significant differences between the βHB-salt+MCT supplement and the PLA were observed for average HR (173.1 ± 15.7 and 178.8 ± 7.9 bpm, respectively; *p* = 0.322; ES = 0.46), average VO~2~ (3.0 ± 0.5 and 3.0 ± 0.5 L.min^-1^, respectively; *p* = 0.665; ES = 0.08), average VCO~2~ (3.0 ± 0.6 and 2.9 ± 0.6 L.min^-1^, respectively; *p* = 0.521; ES = 0.12), average RER (0.99 ± 0.04 and 0.98 ± 0.04, respectively; *p* = 0.655; ES = 0.24), average V~E~ (70.9 ± 14.8 and 69.4 ± 15.0 L.min^-1^, respectively; *p* = 0.607; ES = 0.10), average affect (2.3 ± 1.8 and 1.8 ± 1.8, respectively; *p* = 0.143; ES = 0.28), average RPE-O (5.5 ± 1.3 and 5.3 ± 1.4, respectively; *p* = 0.593; ES = 0.15), average session RPE (6.2 ± 1.3 and 7.3 ± 1.6, respectively; *p* = 0.093; 0.76), and average session affect (2.6 ± 1.6 and 2.0 ± 2.3, respectively; *p* = 0.456; ES = 0.30) ([Table 2](#j_hukin-2019-0114_tab_002){ref-type="table"}).

![Impact of exogenous ketone supplementation on blood R-β-hydroxybutyrate, glucose, and lactate. A) Blood R-β-hydroxybutyrate was higher 60 min post-supplement and remained elevated throughout exercise in the oral ketone condition. B) Blood glucose rose during exercise but was not affected by oral ketone supplementation. C) Blood lactate rose during exercise, but was not affected by oral ketone supplementation. Values are Mean ± SD. (N = 10). \*Significant difference between Ketone and Placebo conditions (p \< 0.05).](hukin-72-115-g002){#j_hukin-2019-0114_fig_002}

Discussion {#j_hukin-2019-0114_s_004}
==========

The purpose of this study was to determine whether a commercially available exogenous ketone mixture of βHB-salt+MCT would impact physiologic, metabolic, perceptional, and performance responses to intermediate distance running performance in recreational, college-age endurance athletes. We hypothesized that the βHB-salt+MCT drink would alter blood metabolites and metabolism, but neither perception nor athletic performance. This is the first study to examine the effect of a commercially available ketone supplement on 5-km running performance in recreational male distance runners. The major finding of this study was that ingesting 300mg.kg^-1^ body mass of an βHB-salt+MCT drink 60 min before exercise resulted in a non-significant 4.06% improvement in 5-km treadmill running time (*p* = 0.100). Furthermore, low variability of 5-km time trials established in our laboratory and among endurance-trained distance runners (typical error of measurement of 31.75 s with a coefficient of variation of 2.18%) suggests that altered endurance performance likely resulted from the ketone supplement ingestion ([@j_hukin-2019-0114_ref_028]). Additional analysis did show significant differences in circulating *R*-βHB, with no differences in other metabolic, physiologic, and perception variables. Together, results indicate a mixed response across participants after consuming 300 mg.kg^-1^ βHB-salt+MCT supplement prior to exercise with 80% deemed responders and 20% non-responders.

Exogenous ketone supplements have emerged as a powerful and viable tool for regulating metabolism. Exogenous ketone formulations have been shown to safely raise circulating ketone levels and alter blood glucose ([@j_hukin-2019-0114_ref_014]). This analysis looked at βHB-salt, MCT, βHB-salt+MCT, ketone ester, and 1,3-butanediol, demonstrating differential metabolic responses across the various exogenous ketone formulations tested. Ketone esters are widely considered the most potent exogenous ketone supplement and various agents are starting to enter the commercial market. 1,3-butanediol acetoacetate diester, a ketone ester, has recently been shown to reduce body mass and adiposity in obese mice, supporting the idea that ketones change energy metabolism ([@j_hukin-2019-0114_ref_006]). MCTs are naturally occurring in a variety of animal and vegetable fat, but can be consumed in a supplemental form. MCTs are ingested, shuttled to the hepatocyte inner mitochondrial membrane, and readily converted to *R*-βHB since they do not require carnitine to undergo β-oxidation ([@j_hukin-2019-0114_ref_002]; [@j_hukin-2019-0114_ref_032]). βHB-salts are typically in a racemic mixture of 50% *R*-βHB and 50% *S*-βHB ([@j_hukin-2019-0114_ref_036]). To synthesize these molecules, βHB is ionically bound to monovalent or divalent cations (Na^+^, K^+^, Mg^2+^, Ca^2+^) to create a salt. Thus, βHB-salts accompany a mineral load depending on the choice and proportion of cation used to synthesize the salt. Upon ingestion, βHB-salts are absorbed through intestinal MCT transporters and enter systemic circulation where they can be readily metabolized in extra-hepatic tissue. *S*-βHB appears to undergo differential metabolic pathways than *R*-βHB ([@j_hukin-2019-0114_ref_007]; [@j_hukin-2019-0114_ref_036], [@j_hukin-2019-0114_ref_037]) but does have some similar signaling capabilities ([@j_hukin-2019-0114_ref_020]). βHB-salt+MCT extends the circulating elevation of *R-*βHB further than when βHB-salt-only is administered ([@j_hukin-2019-0114_ref_014]).

Unsurprisingly, βHB-salt+MCT significantly elevated circulating *R-*βHB levels 2-fold (0.3 to 0.6 mM) in our findings. Similar elevations in circulating *R-*βHB have been seen in other trials with βHB-salt supplementation ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_036]; [@j_hukin-2019-0114_ref_039]). However, total βHB levels reported across these trails and ours, underestimate the total circulating βHB levels, as *S-*βHB is undetectable by current meter and bench top assay kits ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]) and requires mass spectrum analysis ([@j_hukin-2019-0114_ref_037]). [@j_hukin-2019-0114_ref_036] demonstrated that when a racemic βHB-salt compound is orally administered, both *R-*βHB and *S-*βHB become elevated, but *S-*βHB is elevated to a higher degree due to its believed delayed metabolism. Thus, our results and others using βHB-salts underestimate total βHB ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]). While knowing total βHB is important for predicted systemic effect and cellular signaling, *S-*βHB is not fully metabolized through the ketolysis pathway and may not be consequential on the energetics of exercise performance in the present study ([@j_hukin-2019-0114_ref_037]). *S*-βHB may play an important role in signaling that is being investigated for its protective effects ([@j_hukin-2019-0114_ref_020]).

*R-*βHB elevations were observed in all studies involving βHB-salts ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_036]; [@j_hukin-2019-0114_ref_039]), including our present findings, but were substantially lower than those achieved via ketone esters ([@j_hukin-2019-0114_ref_004]; [@j_hukin-2019-0114_ref_008]; [@j_hukin-2019-0114_ref_016]; [@j_hukin-2019-0114_ref_036]). Additionally, serum glucose levels did not substantially change in the current study compared to the placebo, a finding that has been previously reported with ingestion of βHB-salts ([@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]). However, this is not consistently reported ([@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_036]). Lactate is a substrate biomarker for glycolytic metabolism and is commonly elevated post-exercise. Initial report on ketone ester ingestion demonstrated lower lactate production during exercise ([@j_hukin-2019-0114_ref_004]), which was confirmed by two subsequent analyses of various ketone ester formulations ([@j_hukin-2019-0114_ref_008]; [@j_hukin-2019-0114_ref_016]). However, this is dissimilar to the augmented ([@j_hukin-2019-0114_ref_038]) and neutral effects ([@j_hukin-2019-0114_ref_041]) reported on exercise lactate production with VLCKD. Exogenous ketone-induced attenuated lactate production was initially proposed as a glucose sparring mechanism which allowed for glucose to be present for anaerobic efforts at the end of a race ([@j_hukin-2019-0114_ref_004]). However, others have speculated on the potential for ketones to attenuate glucose utilization and subsequent lactate production, potentially inhibiting performance ([@j_hukin-2019-0114_ref_008]; [@j_hukin-2019-0114_ref_016]). Some argue that this may be a consequence of changes seen in pyruvate dehydrogenase activity as has been seen in low-carbohydrate dietary regimens ([@j_hukin-2019-0114_ref_035]). However, it is currently unknown whether changes in pyruvate dehydrogenase activity occur consistently with acute ketone administration and whether this will influence performance. Additionally, an attenuation of lactate production has not been reported in any trial using βHB-salts ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]), which agrees with our findings and those by [@j_hukin-2019-0114_ref_041] using a VLCKD. Taken together, our metabolic data indicate that consumption of βHB-salt+MCT results in significantly elevated circulation of βHB, a finding that is reported across all exogenous ketone supplements ([@j_hukin-2019-0114_ref_036]; [@j_hukin-2019-0114_ref_016]). However, we did not find changes in blood glucose levels, which is consistent with some reports using βHB-salt ([@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]), and inconsistent with others ([@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_036]). Together, these results indicate mixed results on the blood glucose lowering effects of βHB-salt administration. Additionally, the unchanged lactate levels reported in the present study indicate that higher levels of circulating ketones may be required to attenuate lactate production, an effect that has been seen with more potent forms of exogenous ketone administration ([@j_hukin-2019-0114_ref_004]; [@j_hukin-2019-0114_ref_008]; [@j_hukin-2019-0114_ref_016]), but not found in βHB-salt administration ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]). Interestingly, the augmented ([@j_hukin-2019-0114_ref_038]) and neutral effects ([@j_hukin-2019-0114_ref_041]) of a VLCKD on exercise lactate production highlight potential metabolic overlap and discrepancies between a VLCKD and various exogenous ketone formulations.

Substrate utilization is commonly extrapolated from the amount of O~2~ consumed and CO~2~ expelled ([@j_hukin-2019-0114_ref_013]). Previous analyses of βHB-salt under such calculations were extrapolated to indicate that βHB-salts may increase fat-oxidation ([@j_hukin-2019-0114_ref_021]). However, such assumptions during ketone supplementation without adjustment calculations may not be valid ([@j_hukin-2019-0114_ref_008]). Equating substrate utilization from RER measurements cannot be reliably done without adjusting calculations for ketone supplementation as RER of βHB and AcAc are 0.89 and 1.00, respectively, directly confounding calculations of glucose and fat oxidation ([@j_hukin-2019-0114_ref_011]). Thus, substrate level utilization cannot be determined from the present study or others testing βHB-salts ([@j_hukin-2019-0114_ref_021]). Additionally, while RER was not significantly different within the current study, RER has had inconsistent results in previous analysis involving βHB-salts with some indicating lower RER ([@j_hukin-2019-0114_ref_021]), and some indicating higher ([@j_hukin-2019-0114_ref_009]; [@j_hukin-2019-0114_ref_031]).

Finally, we did not find a performance-enhancing effect across the mean of all 10 participants, although a non-significant decrease in time to completion of 4.06% (\~60 seconds) was observed (*p* = 0.100). To date, only three studies have analyzed βHB-salts as an ergogenic or ergolytic supplement in performance outcomes:

1.  a 15-min staged exercise regimen prior to a 10 km cycling time trial ([@j_hukin-2019-0114_ref_021]).

2.  a 90 min steady-state bout of cycling at 80% of the ventilatory threshold, followed by a 4-km time trial ([@j_hukin-2019-0114_ref_031])

3.  a 5 min warm up prior to four 15 s maximum effort intervals ([@j_hukin-2019-0114_ref_039]).

Two of the three trials showed no difference when aerobic activity was used prior to an analyzed intense anaerobic environment thereafter, both using various cycling exercise regimens ([@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]). However, one of the trials showed a 6.9% slower time and 7% lower power output during time trial completion using graded cycling exercise (30%, 60%, 90% of ventilatory threshold) followed by a measured 10-km time trial ([@j_hukin-2019-0114_ref_021]), with two subjects performing worse. However, our data indicate a mixed response across participants consuming the βHB-salt+MCT combination.

One potential explanation for the alternative response reported is the type of exercise regimen utilized in the present analysis, i.e., running. Alternatively, all previous analysis into βHB-salts with neutral or negative effects utilized cycling as exercise of choice ([@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]), indicating potential supplemental sport ergogenic specificity. A more likely explanation for the result discrepancy in the present trial is the lack of preliminary exhaustive exercise prior to the 5-km time trial. The likely rational for providing exhaustive exercise prior to a time trial performance is to replicate the race environment where the final stretch of the race requires all out (timed) effort and thus can have influence on the final race performance and finish. Experimental designs may also be influenced by the original work done in cyclists using the ketone ester which involved a preliminary steady state exercise regimen for 60 min followed by a 30-min time trial ([@j_hukin-2019-0114_ref_004]). Additionally, the original analysis of ketone ester supplementation indicated that \>1.0 mM elevations in ketone may attenuate glucose utilization or be glycogen sparring ([@j_hukin-2019-0114_ref_004]). However, glucose sparing effect of ketones only appears to happen in the context of ketone ester as they all have shown attenuated lactate production ([@j_hukin-2019-0114_ref_004]; [@j_hukin-2019-0114_ref_008]; [@j_hukin-2019-0114_ref_016]). Lastly, we cannot exclude the possibility that this unique formulation contributed to discrepant performance outcomes when compared with pure racemic βHB-salts as this βHB-salt+MCT formulation contains a higher percentage of *R-*βHB precursors ([@j_hukin-2019-0114_ref_014]), has shown to produce a more prolonged elevations in circulating serum *R-*βHB in rodents, and all historical *R-*βHB analyses in exercised human cohorts demonstrating similar *R-*βHB elevations are limited to timepoint measurements and not total *R-*βHB exposure over study duration ([@j_hukin-2019-0114_ref_021]; [@j_hukin-2019-0114_ref_031]; [@j_hukin-2019-0114_ref_039]).

Limitations of the present study include the method of plasma metabolite analysis, inability to differentiate this supplement used against other fueling strategies, and the inability to directly measure tissue substrate utilization to determine tissue specific effects. Discrepancies have been observed across handheld meters and bench top assays, neither of which assessed total βHB levels in the blood. Mass spectrum analysis is the only method currently available to determine *S*-βHB and total βHB. The present study was conducted to determine the ergolytic or ergogenic influence of a specific formula of βHB-salts+MCT. Consequently, we are unable to determine whether supplementing with βHB-salts+MCT is superior to other known athletic fuel strategies. Lastly, RER measurements are traditionally used to determine fat to carbohydrate oxidation. However, ketone supplementation confounds these measurements and would require a combination of ketone excretion and blood ketone measurements to estimate influence of ketones on substrate level oxidation.

Conclusions {#j_hukin-2019-0114_s_005}
===========

Traditionally, ketosis was only achieved through dietary manipulation. Recent interest has arisen to develop ketone bodies that can be exogenously administered without dietary carbohydrate restriction. With the emergence of commercially available exogenous ketone formulations, research has focused on exploring their use in athletic performance. To our knowledge this is the first study to report the effects of oral ketone supplement ingestion on 5-km treadmill running performance. This investigation demonstrated that recreational endurance athletes consuming a βHB-salt+MCT formula showed a non-significant 4.06% decrease in time to complete volitional 5-km run performance (*p* = 0.100). βHB-salt+MCT consumption did significantly increase blood *R*-βHB levels, with no differences in other metabolic, physiologic, and perception variables. Results indicate that runners may experience mixed responses to consuming a 300 mg.kg^-1^ βHB-salt+MCT supplement prior to exercise. Further testing will be needed to determine if βHB-salts+MCT provides a unique metabolic advantage, and if this altered response is specific to the exercise task.
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